The following table shows the list of Horizon 2020 projects developed by "AGENZIA ITALIANA DEL FARMACO". Projects are ordered by starting date.
Click on table headers to rearrange data.
# | acronym | programme | role | EC contrib. | start | views |
---|---|---|---|---|---|---|
1 | ADAPT-SMART | H2020-EU.3.1.7.13. | participant | 28˙000.00 | 2015-07-01 | 688 |
2 | PARADIGM | H2020-EU.3.1.7. | participant | 50˙000.00 | 2018-03-01 | 582 |
3 | STARS | H2020-EU.3.1.6. | participant | 57˙000.00 | 2019-01-01 | 278 |
totale | 135˙000.00 |
This organization collaborated with partners in 22 countries.
Within the project ADAPT-SMART this organization got in touch with:
role | cy | shortname | name |
---|---|---|---|
participant | CH | SHIRE | SHIRE INTERNATIONAL GMBH (PRC) |
participant | UK | AbbVie | AbbVie Ltd (PRC) |
participant | BE | UCB | UCB BIOPHARMA SRL (PRC) |
participant | FR | Lysogene | LYSOGENE (PRC) |
participant | BE | EFPIA | FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES (OTH) |
participant | UK | Astellas | ASTELLAS PHARMA EUROPE LTD (PRC) |
participant | NL | ZIN | ZORGINSTITUUT NEDERLAND (PUB) |
participant | FR | IPSEN | IPSEN INNOVATION SAS (PRC) |
participant | FR | HAS | HAUTE AUTORITE DE SANTE (PUB) |
participant | FR | EURORDIS | EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION (OTH) |
participant | US | MSD | MERCK SHARP & DOHME CORP (PRC) |
participant | UK | NICE | NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (PUB) |
participant | US | BMS | BRISTOL-MYERS SQUIBB COMPANY CORP (PRC) |
participant | BE | Amgen | AMGEN (PRC) |
participant | UK | Eli Lilly | Eli Lilly and Company Limited (PRC) |
participant | UK | EMA | THE EUROPEAN MEDICINES AGENCY (PUB) |
coordinator | NL | LYGATURE | STICHTING LYGATURE (OTH) |
participant | FR | IRIS | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER (PRC) |
participant | DE | Bayer | Bayer Pharma AG (PRC) |
participant | US | MIT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (HES) |
participant | UK | PFIZER | PFIZER LIMITED (PRC) |
participant | FR | SARD | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (PRC) |
participant | DE | BI | BOEHRINGER INGELHEIM INTERNATIONALGMBH (PRC) |
participant | BE | JANSSEN | JANSSEN PHARMACEUTICA NV (PRC) |
participant | DK | DHMA | SUNDHEDSSTYRELSEN (PUB) |
participant | LU | EPF | FORUM EUROPEEN DES PATIENTS (FPE) (OTH) |
participant | CH | ROCHE | F. HOFFMANN-LA ROCHE AG (PRC) |
participant | CH | NOVARTIS | NOVARTIS PHARMA AG (PRC) |
participant | DK | Lundbeck | H. LUNDBECK AS (PRC) |
participant | UK | GSK | GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. (PRC) |
participant | DK | Novo Nordisk | NOVO NORDISK A/S (PRC) |
participant | SE | MEDIMMUNE | ASTRAZENECA AB (PRC) |
participant | DE | Merck | MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN (PRC) |
participant | UK | UOXF | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (HES) |
Within the project PARADIGM this organization got in touch with:
role | cy | shortname | name |
---|---|---|---|
participant | BE | Alexion | ALEXION SERVICES EUROPE SPRL (PRC) |
participant | CA | HTAi | HEALTH TECHNOLOGY ASSESSMENT INTERNATIONAL SOCIETY (OTH) |
participant | BE | Synergist | THE SYNERGIST (OTH) |
participant | UK | ABPI | THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY (OTH) |
participant | DE | Bayer AG | BAYER AKTIENGESELLSCHAFT (PRC) |
participant | BE | UCB | UCB BIOPHARMA SRL (PRC) |
participant | UK | Amgen | AMGEN LIMITED (PRC) |
participant | BE | EFPIA | FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES (OTH) |
participant | NL | STICHTING VU | STICHTING VU (HES) |
participant | DE | VFA | VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV (OTH) |
participant | FR | EURORDIS | EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION (OTH) |
participant | DE | GRT | GRUNENTHAL GMBH (PRC) |
participant | UK | Covance | COVANCE LABORATORIES LTD (PRC) |
participant | US | MSD | MERCK SHARP & DOHME CORP (PRC) |
participant | ES | SYNAPSE | SYNAPSE RESEARCH MANAGEMENT PARTNERS SL (PRC) |
participant | UK | Eli Lilly | Eli Lilly and Company Limited (PRC) |
participant | FR | IRIS | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER (PRC) |
participant | LU | AE | ALZHEIMER EUROPE (OTH) |
participant | UK | PFIZER | PFIZER LIMITED (PRC) |
participant | FR | SARD | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (PRC) |
participant | BE | JANSSEN | JANSSEN PHARMACEUTICA NV (PRC) |
participant | ES | IACS | INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD (REC) |
participant | DE | EATG | EUROPEAN AIDS TREATMENT GROUP EV (OTH) |
coordinator | LU | EPF | FORUM EUROPEEN DES PATIENTS (FPE) (OTH) |
participant | ES | FSJD | FUNDACIO SANT JOAN DE DEU (REC) |
participant | CH | ROCHE | F. HOFFMANN-LA ROCHE AG (PRC) |
participant | CH | NOVARTIS | NOVARTIS PHARMA AG (PRC) |
participant | DK | Lundbeck | H. LUNDBECK AS (PRC) |
participant | UK | GSK | GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. (PRC) |
participant | DK | Novo Nordisk | NOVO NORDISK A/S (PRC) |
participant | BE | EFGCP | EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE (OTH) |
participant | DE | Merck | MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN (PRC) |
participant | UK | UOXF | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (HES) |
Within the project STARS this organization got in touch with:
role | cy | shortname | name |
---|---|---|---|
participant | LV | SAMLV | ZALU VALSTS AGENTURA (PUB) |
participant | LT | VVKT | VALSTYBINE VAISTU KONTROLES TARNYBAPRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS (PUB) |
participant | UK | MHRA | MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (PUB) |
participant | FI | FIMEA | LAAKEALAN TURVALLISUUS-JA KEHITTAMISKESKUS (REC) |
participant | PL | URPLWMiPB | URZAD REJESTRACJI PRODUKTOW LECZNICZYCH, WYROBOW MEDYCZNYCH I PRODUKTOW BIOBOJCZYCH (PUB) |
participant | CZ | SÚKL | STATNI USTAV PRO KONTROLU LECIV (PUB) |
participant | IE | HPRA | HEALTH PRODUCTS REGULATORY AUTHORITY (PUB) |
participant | NL | MEB | AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN (PUB) |
participant | FR | ANSM | AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (PUB) |
participant | HU | OGYEI | ORSZAGOS GYOGYSZERESZETI ES ELELMEZES-EGESZSEGUGYI INTEZET (REC) |
participant | BE | AFMPS | FEDERAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS (REC) |
participant | PT | INFARMED | INFARMED - AUTORIDADE NACIONAL DO MEDICAMENTO E PRODUTOS DA SAUDE IP (PUB) |
participant | MT | MA | THE MEDICINES AUTHORITY (PUB) |
participant | NL | EMA | THE EUROPEAN MEDICINES AGENCY (PUB) |
participant | DE | PEI | BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL (PUB) |
participant | AT | AGES | OSTERREICHISCHE AGENTUR FUR GESUNDHEIT UND ERNAHRUNGSSICHERHEIT GMBH (REC) |
coordinator | DE | BfArM | BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE (PUB) |
participant | SE | MPA | LAKEMEDELSVERKET (PUB) |
participant | ES | AEMPS | AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS (PUB) |
participant | DE | DLR | DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV (REC) |